Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas - PubMed (original) (raw)
. 2000 Mar 1;60(5):1383-7.
Affiliations
- PMID: 10728703
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
L Frederick et al. Cancer Res. 2000.
Abstract
Several types of epidermal growth factor receptor (EGFR) gene mutations have been reported in glioblastomas, and in nearly all cases the alterations have been reported in tumors with EGFR amplification. The objectives of this study were to determine the frequency and diversity of EGFR mutations in glioblastomas and to determine whether gene mutation is inevitably associated with increased EGFR gene dosage. To accomplish these aims, we sequenced cDNA products representing the entire EGFR coding region in 44 glioblastomas, half of which had EGFR amplification. Coding sequence alterations were identified in 17 of the tumors, and each of these cases had amplified EGFR. No mutations were identified in the 22 tumors without EGFR amplification. An additional 26 glioblastomas with EGFR amplification were then examined to establish more reliable frequencies for each type of mutation identified in the tumors for which the entire gene was sequenced. Transcripts associated with the most common mutation lacked coding sequence for amino acids 6-273 (67%). This mutation has been described extensively in the literature. Transcripts encoding receptors that would truncate at amino acid 958 and transcripts encoding receptors that would lack amino acids 521-603 were the next most common types of alteration. Each of these were observed in 15% of the tumors with EGFR amplification. Other mutations were observed at lower frequencies, but among these were three cases with missense mutations. Sixteen of the 48 tumors with EGFR amplification showed multiple types of EGFR mutations (33%), and in one case it was determined that multiple alterations had occurred in the same transcript. In total, these data are consistent with EGFR mutation being exclusively and frequently associated with EGFR amplification. Furthermore, the determination of multiple EGFR mutations within individual tumors suggests that glioblastomas with EGFR amplification have the capacity to produce a variety of functionally distinct EGFRs.
Similar articles
- Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Aghi M, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8600-5. doi: 10.1158/1078-0432.CCR-05-0713. Clin Cancer Res. 2005. PMID: 16361543 - Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.
Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Crinière E, Carvalho Silva R, Laigle-Donadey F, Rousseau A, Mokhtari K, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY. Idbaih A, et al. Neuropathol Appl Neurobiol. 2009 Apr;35(2):208-13. doi: 10.1111/j.1365-2990.2008.00977.x. Neuropathol Appl Neurobiol. 2009. PMID: 19284481 - Amplified genes in human gliomas.
Collins VP. Collins VP. Semin Cancer Biol. 1993 Feb;4(1):27-32. Semin Cancer Biol. 1993. PMID: 8448375 Review. - Molecular genetic analysis of deep-seated glioblastomas.
Hayashi Y, Yamashita J, Watanabe T. Hayashi Y, et al. Cancer Genet Cytogenet. 2004 Aug;153(1):64-8. doi: 10.1016/j.cancergencyto.2003.12.010. Cancer Genet Cytogenet. 2004. PMID: 15325097 Review.
Cited by
- Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.
Kersh AE, Sasaki M, Cooper LA, Kissick HT, Pollack BP. Kersh AE, et al. Front Pharmacol. 2016 Sep 26;7:327. doi: 10.3389/fphar.2016.00327. eCollection 2016. Front Pharmacol. 2016. PMID: 27729860 Free PMC article. Review. - Gaps and Doubts in Search to Recognize Glioblastoma Cellular Origin and Tumor Initiating Cells.
Wlodarczyk A, Grot D, Stoczynska-Fidelus E, Rieske P. Wlodarczyk A, et al. J Oncol. 2020 Jul 22;2020:6783627. doi: 10.1155/2020/6783627. eCollection 2020. J Oncol. 2020. PMID: 32774372 Free PMC article. Review. - Predictive and prognostic markers in human glioblastomas.
Palanichamy K, Erkkinen M, Chakravarti A. Palanichamy K, et al. Curr Treat Options Oncol. 2006 Nov;7(6):490-504. doi: 10.1007/s11864-006-0024-7. Curr Treat Options Oncol. 2006. PMID: 17032561 Review. - Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives.
Katt WP, Aplin C, Cerione RA. Katt WP, et al. Onco Targets Ther. 2022 Mar 19;15:277-290. doi: 10.2147/OTT.S329262. eCollection 2022. Onco Targets Ther. 2022. PMID: 35340676 Free PMC article. Review. - A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. Macy ME, et al. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26621. doi: 10.1002/pbc.26621. Epub 2017 May 24. Pediatr Blood Cancer. 2017. PMID: 28544128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous